MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 142 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,259,998 | +193.8% | 25,840 | +252.0% | 1.36% | +140.0% |
| Q4 2022 | $2,130,725 | +51.9% | 7,341 | -66.0% | 0.57% | +42.1% |
| Q3 2022 | $1,403,000 | -8.1% | 21,590 | +1.2% | 0.40% | -29.0% |
| Q2 2022 | $1,527,000 | -23.1% | 21,336 | +5.5% | 0.56% | -3.3% |
| Q1 2022 | $1,985,000 | -18.3% | 20,230 | -29.4% | 0.58% | +8.4% |
| Q4 2021 | $2,429,000 | -3.0% | 28,670 | -8.7% | 0.54% | -15.5% |
| Q3 2021 | $2,505,000 | -29.3% | 31,393 | -13.7% | 0.63% | -18.2% |
| Q2 2021 | $3,545,000 | -23.7% | 36,393 | -8.4% | 0.78% | -28.1% |
| Q1 2021 | $4,646,000 | +222.0% | 39,721 | +206.1% | 1.08% | +191.4% |
| Q4 2020 | $1,443,000 | -33.3% | 12,976 | -28.7% | 0.37% | -35.3% |
| Q3 2020 | $2,162,000 | -61.8% | 18,211 | -63.6% | 0.57% | -64.1% |
| Q2 2020 | $5,663,000 | +182.7% | 50,000 | +66.7% | 1.60% | +71.9% |
| Q1 2020 | $2,003,000 | – | 30,000 | – | 0.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthCor Management, L.P. | 902,601 | $100,342,000 | 3.87% |
| L1 Capital Pty Ltd | 113,464 | $12,608,000 | 2.35% |
| Avoro Capital Advisors LLC | 1,225,000 | $136,183,000 | 2.34% |
| Tao Capital Management LP | 51,396 | $5,714,000 | 1.40% |
| ARMISTICE CAPITAL, LLC | 316,000 | $35,130,000 | 1.20% |
| ACUTA CAPITAL PARTNERS, LLC | 32,500 | $3,613,000 | 0.98% |
| Capital Impact Advisors, LLC | 24,351 | $2,707,000 | 0.66% |
| Baker Brothers Advisors | 1,499,213 | $166,668,000 | 0.63% |
| Rock Springs Capital Management LP | 256,768 | $28,545,000 | 0.60% |
| SHIKIAR ASSET MANAGEMENT INC | 12,000 | $1,334,000 | 0.48% |